Sam Norton1,2, Benjamin Ellis3, Beatriz Santana Suárez1, Samana Schwank1, Ray Fitzpatrick4, Andrew Price5, James Galloway1. 1. Academic Rheumatology, Faculty of Life Sciences and Medicine, London, UK. 2. Psychology Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. 3. Rheumatology Department, Imperial College Healthcare NHS Trust, London, UK. 4. Nuffield Department of Population Health, University of Oxford, Oxford, UK. 5. Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK.
Abstract
Objectives: The Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed Patient Reported Outcome Measure for use across patients with musculoskeletal conditions. This study provides a validation of the MSK-HQ examining construct validity and reliability in inflammatory arthritis. Methods: 287 adults with inflammatory arthritis completed the MSK-HQ and other Patient Reported Outcome Measures at baseline and after 3 months. Construct validity was assessed using item response theory methods. Concurrent validity was considered in relation to the HAQ and EuroQol-5D in all patients, as well as the RA Impact of Disease (RAID), PsA Impact of Disease scales, and AS Quality of Life Questionnaire (ASQoL) in disease subtypes. Results: The MSK-HQ was approximately normally distributed with no evidence of floor or ceiling effects. A unidimensional structure was confirmed. Two items were less weakly related to the latent musculoskeletal health variable, providing some evidence of multidimensionality. Reliability was high (α = 0.93). The total score correlated highly with the HAQ (r = -0.81) and EuroQol-5D index (r = 0.80) in all patients, RAID in RA patients (r = -0.88), PsA Impact of Disease in PsA patients (r = -0.88), and ASQoL in AS patients (r = -0.86). Test-retest reliability was high (rICC = 0.73). Conclusion: This study provides evidence for the validity and reliability of the MSK-HQ in people with inflammatory arthritis. The major advantage of the MSK-HQ is that it is not disease specific and has high content validity in rheumatological conditions. The MSK-HQ score will be of value in clinical rheumatology practice, providing a measure that can be used across disease areas.
Objectives: The Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed Patient Reported Outcome Measure for use across patients with musculoskeletal conditions. This study provides a validation of the MSK-HQ examining construct validity and reliability in inflammatory arthritis. Methods: 287 adults with inflammatory arthritis completed the MSK-HQ and other Patient Reported Outcome Measures at baseline and after 3 months. Construct validity was assessed using item response theory methods. Concurrent validity was considered in relation to the HAQ and EuroQol-5D in all patients, as well as the RA Impact of Disease (RAID), PsA Impact of Disease scales, and AS Quality of Life Questionnaire (ASQoL) in disease subtypes. Results: The MSK-HQ was approximately normally distributed with no evidence of floor or ceiling effects. A unidimensional structure was confirmed. Two items were less weakly related to the latent musculoskeletal health variable, providing some evidence of multidimensionality. Reliability was high (α = 0.93). The total score correlated highly with the HAQ (r = -0.81) and EuroQol-5D index (r = 0.80) in all patients, RAID in RApatients (r = -0.88), PsA Impact of Disease in PsA patients (r = -0.88), and ASQoL in AS patients (r = -0.86). Test-retest reliability was high (rICC = 0.73). Conclusion: This study provides evidence for the validity and reliability of the MSK-HQ in people with inflammatory arthritis. The major advantage of the MSK-HQ is that it is not disease specific and has high content validity in rheumatological conditions. The MSK-HQ score will be of value in clinical rheumatology practice, providing a measure that can be used across disease areas.
Authors: Laure Gossec; Maarten de Wit; Uta Kiltz; Juergen Braun; Umut Kalyoncu; Rossana Scrivo; Mara Maccarone; Laurence Carton; Kati Otsa; Imre Sooäär; Turid Heiberg; Heidi Bertheussen; Juan D Cañete; Anselm Sánchez Lombarte; Andra Balanescu; Alina Dinte; Kurt de Vlam; Josef S Smolen; Tanja Stamm; Dora Niedermayer; Gabor Békés; Douglas Veale; Philip Helliwell; Andrew Parkinson; Thomas Luger; Tore K Kvien Journal: Ann Rheum Dis Date: 2014-06 Impact factor: 19.103
Authors: Maarten Boers; John R Kirwan; George Wells; Dorcas Beaton; Laure Gossec; Maria-Antonietta d'Agostino; Philip G Conaghan; Clifton O Bingham; Peter Brooks; Robert Landewé; Lyn March; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell Journal: J Clin Epidemiol Date: 2014-02-28 Impact factor: 6.437
Authors: Lidwine B Mokkink; Caroline B Terwee; Donald L Patrick; Jordi Alonso; Paul W Stratford; Dirk L Knol; Lex M Bouter; Henrica C W de Vet Journal: Qual Life Res Date: 2010-02-19 Impact factor: 4.147
Authors: Jonathan C Hill; Sujin Kang; Elena Benedetto; Helen Myers; Steven Blackburn; Stephanie Smith; Kate M Dunn; Elaine Hay; Jonathan Rees; David Beard; Sion Glyn-Jones; Karen Barker; Benjamin Ellis; Ray Fitzpatrick; Andrew Price Journal: BMJ Open Date: 2016-08-05 Impact factor: 2.692